{"changeSha256":"956913912826ee4962d05fa7d90c422238013c450900cea4feed21934d218803","changedAt":"2026-11-14","changedFields":[{"after":"A 15-amino-acid research peptide that is not FDA-approved. FDA’s 2026 review found only a few small, short human studies.","before":"A research peptide represented by FDA compounding-review material and one selected trial-registry record.","field":"Profile summary"},{"after":"FDA staff recommended in May 2026 against adding BPC-157 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists BPC-157 among six peptides that may be compounded under set conditions without federal enforcement action; it does not make BPC-157 an FDA-approved drug.","before":"FDA presented BPC-157 briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding and FDA's final determination remains pending; the cited trial registration also does not establish safety or effectiveness.","field":"Evidence note"},{"after":"Body protection compound 157, Bepecin, PL 14736","before":"Body protection compound 157","field":"Related names"},{"after":"fda-bpc-157-briefing, fda-bulk-peptide-risks, ctg-nct07437547-v1, fda-pcac-peptide-meeting-2026, ctg-observation-nct07803250-2026-09-03-67a2d48128fc, federal-register-2026-07361-0aed508462b2, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"fda-bpc-157-briefing, fda-bulk-peptide-risks, ctg-nct07437547-v1, fda-pcac-peptide-meeting-2026","field":"Cited source records"},{"after":"U.S. Food and Drug Administration [sources: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026]; Hudson Biotech [sources: ctg-nct07437547-v1]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]","before":"U.S. Food and Drug Administration [sources: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026]; Hudson Biotech [sources: ctg-nct07437547-v1]","field":"Named organizations"},{"after":"name: fda-bpc-157-briefing; aliases: fda-bpc-157-briefing; category: fda-bpc-157-briefing, fda-bulk-peptide-risks, fda-pcac-peptide-meeting-2026; status: fda-bpc-157-briefing; summary: fda-bpc-157-briefing; evidenceNote: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"name: fda-bpc-157-briefing; aliases: fda-bpc-157-briefing; category: fda-bpc-157-briefing, fda-bulk-peptide-risks, fda-pcac-peptide-meeting-2026; status: fda-bpc-157-briefing; summary: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026, ctg-nct07437547-v1; evidenceNote: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026, ctg-nct07437547-v1","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/bpc-157/versions/3/","version":3},"id":"profile:bpc-157:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We added a plain-language reader guide with cited answers, re-checked FDA’s BPC-157 records, added a second registered trial, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists BPC-157. FDA has not issued a final 503A rule.","peptideSlugs":["bpc-157"],"previousChangeEvent":{"path":"/corrections/v1/profiles/bpc-157/v2.json","sha256":"e38b3d3cf24a386ccd1d5073436a2dcea4a66bc859ea2673ae9c2b5bf8920841"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/bpc-157/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-bpc-157-briefing","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA briefing document for BPC-157-related bulk drug substances","url":"https://www.fda.gov/media/193343/download","verifiedAt":"2026-11-14"},{"id":"hhs-503a-peptide-enforcement-discretion-notice-2026","name":"Federal Register · U.S. Department of Health and Human Services","sourceClass":"A","title":"Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026","url":"https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances","verifiedAt":"2026-11-14"},{"id":"hhs-503a-peptide-enforcement-discretion-policy-2026","name":"U.S. Department of Health and Human Services","sourceClass":"A","title":"HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications)","url":"https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf","verifiedAt":"2026-11-14"}],"subject":{"slug":"bpc-157","type":"profile"}}
